Pipeline-with-milestones

We are building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases

  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II

NEXT ANTICIPATED MILESTONE

CBP-201

Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)

Atopic Dermatitis
  •  
  •  
  •  
  •  
Asthma
  •  
  •  
  •  
  •  
Nasal Polyps
  •  
  •  
  •  
  •  
  • Submit NDA by end of first quarter 2024
  • Secure partnership to advance Global Ph3
  • Topline readout in second half of 2023

CBP-307

Small molecule targeting S1P1 (Th1 cell modulator)

Ulcerative Colitis
  •  
  •  
  •  
  •  
Crohn's Disease
  •  
  •  
  •  
  •  
  • Maintenance data targeted for second quarter 2023
  • Seeking partnerships to advance into future trials for both indications

CBP-174

Small molecule (target undisclosed)

Pruritis
  •  
  •  
  •  
  •  
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors